Nectin-4在妇科恶性肿瘤中的研究进展  

Research Progress of Nectin-4 in Gynecologic Malignancies

作　　者：张昊晟 魏芳(审校)[2] ZHANG Hao-sheng;WEI Fang(Second Clinical Medical College,Shanxi Medical University,Taiyuan 030001,China;Department of Obstetrics and Gynecology,Second Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二临床医学院,太原030001 [2]山西医科大学第二医院妇产科

出　　处：《国际妇产科学杂志》2025年第2期165-168,共4页Journal of International Obstetrics and Gynecology

摘　　要：连接蛋白-4(Nectin-4)是一种与肿瘤相关的细胞黏附分子,在多种妇科恶性肿瘤(如宫颈癌、卵巢癌和子宫内膜癌)中高表达,与肿瘤的发生、发展及预后密切相关。近年来,Nectin-4已成为抗体药物偶联物(antibody-drug conjugate,ADC)开发的重要靶点。恩诺单抗(Enfortumab vedotin,EV)是一种靶向Nectin-4的ADC,已获美国食品药品监督管理局批准用于尿路上皮癌治疗。然而,目前尚无临床试验直接评估EV在妇科恶性肿瘤中的应用。多项研究表明,Nectin-4在妇科恶性肿瘤中的高表达可能使其成为潜在的治疗靶点。此外,国内自主研发的ADC药物如9MW2821和SHR-A2102正在开展临床试验,有望为妇科恶性肿瘤治疗提供新选择。未来开展针对Nectin-4的ADC在妇科恶性肿瘤中的疗效和安全性研究,有望为耐药的或晚期妇科恶性肿瘤患者的治疗带来新希望。Nectin-4 is a tumor-associated cell adhesion molecule that is highly expressed in various gynecologic malignancies,such as cervical,ovarian,and endometrial cancers,and is closely related to tumor development,progression,and prognosis.In recent years,Nectin-4 has emerged as an important target for the development of antibody-drug conjugate(ADC).Enfortumab vedotin(EV),an ADC targeting Nectin-4,has been approved by the US Food and Drug Administration(FDA)for the treatment of urothelial cancer.However,no clinical trials have directly evaluated the application of EV in gynecologic malignancies.Nevertheless,multiple studies have shown that the high expression of Nectin-4 in gynecologic malignancies may make it a potential therapeutic target.In addition,domestic ADCs such as 9MW2821 and SHR-A2102 are currently in clinical trials and are expected to offer new treatment options for gynecologic malignancies.Future studies on the efficacy and safety of Nectin-4-targeted ADCs in gynecologic malignancies are highly anticipated and may bring new hope to patients with drug resistant or advanced disease.

关 键 词：连接蛋白 生殖器肿瘤 女(雌)性 免疫轭合物 分子靶向治疗 Nectin-4 恩诺单抗 

分 类 号：R737.3[医药卫生—肿瘤]